

Supplementary Table 2. Rates of complete treatment response at 4 weeks, end of treatment, and 12 weeks after treatment

	RVR	ETR	SVR12
All patients (n=5,028)	4,825 (96.0)	5,008 (99.6)	5,008 (99.6)
Genotype 1a (n=23)	16 (69.6)	16 (69.6)	16 (69.6)
Genotype 1b (n=5,005)	4,809 (96.1)	4,992 (99.7)	4,992 (99.7)
IFN-naïve (n=4,947)	4,751 (96.0)	4,927 (99.6)	4,927 (99.6)
IFN-experienced (n=81)	74 (91.4)	81 (100.0)	81 (100.0)
HCV RNA >6,000,000 IU/mL (n=866)	807 (93.2)	861 (99.4)	861 (99.4)
HCV RNA ≤6,000,000 IU/mL (n=4,162)	4,018 (96.5)	4,147 (99.6)	4,147 (99.6)
Liver cirrhosis (n=1,151)	1,090 (94.7)	1,143 (99.3)	1,143 (99.3)
LS* >8.4 kPa (n=2,325)	2,232 (96.0)	2,313 (99.5)	2,313 (99.5)
LS* >9.6 kPa (n=1,721)	1,642 (95.4)	1,710 (99.4)	1,710 (99.4)
LS* >12.8 kPa (n=1,117)	1,057 (94.6)	1,109 (99.3)	1,109 (99.3)
APRI >0.7 (n=2,334)	2,230 (95.5)	2,322 (99.5)	2,322 (99.5)
APRI >1.0 (n=1,604)	1,528 (95.3)	1,595 (99.4)	1,595 (99.4)
FIB-4 ≥1.45 (n=3,165)	3,026 (95.6)	3,150 (99.5)	3,150 (99.5)
FIB-4 ≥3.25 (n=903)	852 (94.4)	895 (99.1)	895 (99.1)

Values are presented as number (%).

RVR, rapid virologic response; ETR, end of treatment response; SVR12, sustained virologic response 12 weeks after end of treatment; IFN, interferon; LS, liver stiffness; APRI, aspartate aminotransferase to platelet ratio index; FIB-4, fibrosis-4.

*Measured by transient elastography.